Mutual of America Capital Management LLC Sells 549 Shares of The Cooper Companies, Inc. (NASDAQ:COO)

Mutual of America Capital Management LLC cut its holdings in The Cooper Companies, Inc. (NASDAQ:COO) by 2.2% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,488 shares of the medical device company’s stock after selling 549 shares during the period. Mutual of America Capital Management LLC’s holdings in Cooper Companies were worth $2,702,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Quent Capital LLC boosted its holdings in shares of Cooper Companies by 300.0% during the 1st quarter. Quent Capital LLC now owns 828 shares of the medical device company’s stock valued at $84,000 after purchasing an additional 621 shares during the last quarter. Acadian Asset Management LLC grew its holdings in Cooper Companies by 300.0% during the 1st quarter. Acadian Asset Management LLC now owns 720 shares of the medical device company’s stock valued at $73,000 after buying an additional 540 shares in the last quarter. Covestor Ltd increased its stake in Cooper Companies by 305.9% in the 1st quarter. Covestor Ltd now owns 276 shares of the medical device company’s stock worth $28,000 after acquiring an additional 208 shares during the last quarter. O Shaughnessy Asset Management LLC raised its holdings in shares of Cooper Companies by 443.6% during the 1st quarter. O Shaughnessy Asset Management LLC now owns 4,876 shares of the medical device company’s stock worth $495,000 after acquiring an additional 3,979 shares in the last quarter. Finally, American International Group Inc. boosted its position in shares of Cooper Companies by 298.7% during the 1st quarter. American International Group Inc. now owns 52,749 shares of the medical device company’s stock valued at $5,352,000 after acquiring an additional 39,520 shares during the last quarter. 24.39% of the stock is currently owned by institutional investors.

Cooper Companies Stock Performance

Shares of Cooper Companies stock opened at $100.80 on Friday. The company has a quick ratio of 1.18, a current ratio of 1.99 and a debt-to-equity ratio of 0.33. The stock’s fifty day moving average is $105.91 and its two-hundred day moving average is $98.29. The Cooper Companies, Inc. has a 52 week low of $82.21 and a 52 week high of $112.38. The company has a market capitalization of $20.07 billion, a PE ratio of 56.00, a price-to-earnings-growth ratio of 2.15 and a beta of 0.99.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings results on Wednesday, August 28th. The medical device company reported $0.96 EPS for the quarter, topping analysts’ consensus estimates of $0.91 by $0.05. Cooper Companies had a net margin of 9.45% and a return on equity of 9.08%. The firm had revenue of $1 billion for the quarter, compared to analysts’ expectations of $997.30 million. During the same period in the prior year, the business posted $0.84 earnings per share. The business’s revenue for the quarter was up 7.8% on a year-over-year basis. As a group, analysts expect that The Cooper Companies, Inc. will post 3.65 earnings per share for the current year.

Insider Transactions at Cooper Companies

In other news, COO Daniel G. Mcbride sold 114,992 shares of the stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $105.48, for a total transaction of $12,129,356.16. Following the transaction, the chief operating officer now owns 44,696 shares of the company’s stock, valued at approximately $4,714,534.08. This represents a 72.01 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Agostino Ricupati sold 1,601 shares of Cooper Companies stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $108.03, for a total value of $172,956.03. Following the completion of the sale, the chief accounting officer now owns 4,818 shares of the company’s stock, valued at $520,488.54. The trade was a 24.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 256,373 shares of company stock valued at $27,637,427. 2.00% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

COO has been the topic of several research reports. Robert W. Baird boosted their price target on shares of Cooper Companies from $118.00 to $125.00 and gave the stock an “outperform” rating in a research report on Thursday, August 29th. Wells Fargo & Company upped their target price on shares of Cooper Companies from $110.00 to $115.00 and gave the company an “overweight” rating in a research report on Thursday, August 29th. Piper Sandler lifted their price target on Cooper Companies from $115.00 to $120.00 and gave the stock an “overweight” rating in a research report on Thursday, August 29th. StockNews.com cut Cooper Companies from a “buy” rating to a “hold” rating in a research note on Wednesday. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Cooper Companies in a research note on Thursday, August 29th. Four equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $117.00.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.